Roy Donald Duncan, MD in Aberdeen, MS - Urology

Roy Donald Duncan, MD is a Urology physician based in Aberdeen, Mississippi. Roy Donald Duncan is licensed to practice in Mississippi (license number 05780) and his current practice location is 300 Forrest Hill Cir, Aberdeen, Mississippi. He can be reached at his office (for appointments etc.) via phone at (228) 343-0650.

NPI number for Roy Donald Duncan is 1881006807 and his current mailing address is 300 Forrest Hill Cir, Aberdeen, Mississippi. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1881006807.

Contact Information

	Roy Donald Duncan, MD
	300 Forrest Hill Cir, Aberdeen, MS 39730-2147
	(228) 343-0650
	Not Available

Physician's Profile

Full Name	Roy Donald Duncan
Gender	Male
Speciality	Urology
Location	300 Forrest Hill Cir, Aberdeen, Mississippi
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1881006807
Provider Enumeration Date: 05/26/2014
Last Update Date: 05/26/2014

Medical Identifiers

Medical identifiers for Roy Donald Duncan such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1881006807	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208800000X	Urology	05780 (Mississippi)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Roy Donald Duncan is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Roy Donald Duncan, MD 300 Forrest Hill Cir, Aberdeen, MS 39730-2147 Ph: (228) 343-0650	Roy Donald Duncan, MD 300 Forrest Hill Cir, Aberdeen, MS 39730-2147 Ph: (228) 343-0650

News Archive

Cell Therapeutics to sell $30 million of Preferred Stock and warrants in registered offering

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $30 million of shares of its Series 13 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to six institutional investors.

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in Orlando, FL (June 25-29, 2010). Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 12 weeks of treatment with ITCA 650 at both the 20 mcg/day and 40 mcg/day doses.

Researchers use computational models to examine how sleep prevents damage to old memories

From lowering your risk of obesity and cardiovascular disease to improving your concentration and overall daily performance, sleep has been proven to play a critical role in our health.

Viewpoints: Komen's retreat; Romney's selected support of Medicare cuts; Heritage refuses blame for individual mandate

A group like Komen only has the quality service it provides and goodwill garnered over the years to encourage donations and support. Its trademark pink is not as bold as before. For the moment, it seems drab and faded.

Roy Donald Duncan, MD - Urology in Aberdeen, MS